Loading...
OTCM
BIXT
Market cap9mUSD
Jun 27, Last price  
0.11USD
1D
-5.70%
1Q
-27.23%
IPO
-85.93%
Name

Bioxytran Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.12%
Rev. gr., 5y
%
Revenues
0k
0016,13276,295312,903417,336275,616255,822246,495191,0770000000
Net income
-2m
L-44.70%
-24,324-276,345-336,470-2,358,416-2,293,258-1,778,536-1,346,900-2,100,129-696,756-318,387-296,417-2,085,485-3,754,444-4,345,353-2,463,932-4,280,002-2,366,681
CFO
-56k
L-92.81%
-3,558-202,465-75,804-450,101-67,19613,466-16,321-2,687-42,389-18,518-185,904-431,033-1,098,992-1,697,399-1,805,670-775,375-55,737

Profile

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
URL
https://www.bioxytraninc.com/
IPO date
Jan 05, 2010
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
1,280
3,828
2,138
Unusual Expense (Income)
NOPBT
(1,280)
(3,828)
(2,138)
NOPBT Margin
Operating Taxes
(13)
(193)
Tax Rate
NOPAT
(1,267)
(3,828)
(1,944)
Net income
(2,367)
-44.70%
(4,280)
73.71%
(2,464)
-43.30%
Dividends
Dividend yield
Proceeds from repurchase of equity
63
550
680
BB yield
Debt
Debt current
853
1,925
2,165
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
848
1,899
1,870
Cash flow
Cash from operating activities
(56)
(775)
(1,806)
CAPEX
(32)
Cash from investing activities
(28)
(44)
(32)
Cash from financing activities
63
550
2,061
FCF
(1,504)
(3,733)
(1,824)
Balance
Cash
5
26
295
Long term investments
Excess cash
5
26
295
Stockholders' equity
(18,791)
(16,033)
(11,685)
Invested Capital
17,852
14,846
10,517
ROIC
ROCE
136.31%
322.57%
183.07%
EV
Common stock shares outstanding
138,599
134,224
115,139
Price
Market cap
EV
EBITDA
(602)
(3,820)
(2,134)
EV/EBITDA
Interest
84
542
520
Interest/NOPBT